This was a superb session. Thank you to the speakers and chairs
This was a superb session. Thank you to the speakers and chairs
Great to see @greg-wells.bsky.social and @ljtl.bsky.social on behalf of the Sheffield ex vivo group. Well done!
Longer hours. But why?
#PhDchat #PhDforum #ECRchat #postdoc
PREPRINT CLAIMING LINK BETWEEN mRNA VACCINES A D CANCER HAS BEEN WITHDRAWN. Thanks @elisabethbik.bsky.social for your vigilance.
We are open to recruitment in Sheffield
The Arts Tower with trees and Weston Park in the foreground
The National Student Survey results are in and we're proud to say that we're top of the Russell Group for the third year in a row! And our Student's Union has been ranked number 1 once again.
A testament to the hard work of our brilliant University community ππ
sheffield.ac.uk/news/sheffie...
Proportion of NHS doctors who carry out research has fallen by a quarter over 13 years despite evidence suggesting hospitals with active research programmes deliver better patient outcomes, finds @policyatkings.bsky.social www.timeshighereducation.com/news/nhs-inn... via @helenpacker.bsky.social
Impressive poster from Dr Sophie Williams @sheffielduni.bsky.social on the microenvironment in GBM. Also her Supervisor @sdanson1.bsky.social #SMPHResearch&Innovation
This is superb news. Something to really celebrate. Thanks to all involved
Great work from Sophie Williams on brain ageing in the glioblastoma tumour microenvironment
Sheffield Ex Vivo Group out in force at Sheffield #smph_research&innovation meeting today. Callum Blee, Louis Lane and Jamie Adams pictured. Great to see
Announcement image - dark blue background with coloured overlapping circles Top shows the Cancer Research UK Manchester Institute Logo Centre shows a photograph of Professor Samra TurajliΔ Text says: "A warm welcome to our new Director, Professor Samra TurajliΔ, from all staff and students at the Cancer Research UK Manchester Institute"
We are delighted to announce, along with Cancer Research UK (@cancerresearchuk.org), The University of Manchester (@manchester.ac.uk) and The Christie NHS Foundation Trust, the appointment of Professor Samra TurajliΔ as our new Director! β
Full story here: www.cruk.manchester.ac.uk/news/profess...
Enjoyed today. Looking forward to hearing more tomorrow
Christine Le Maitre opening our annual meeting #SMPH_Research&Innovation. Apologies I cannot rotate!!
Exciting opportunity to join the cancer research community in Sheffield!!
Huge congratulations, Jim
Didn't I just see you in person??
Yesterday, Professor Sarah Danson presented the results of the UK DANTE trial at the 2025 American Society of Clinical Oncology (ASCO) annual medical meeting.
Read more: buff.ly/arneMoo
#melanoma #melanomacancer #ASCO25
Honoured to present the DANTE trial at ASCO today on behalf of the extended DANTE team. Thank you to all the patients who were involved
Much less clarity on whether or not to continue systemic immunotherapy after pCR following neoadjuvant therapy
The people have spoken, and they are undedecided - more work to do! #melsm #ASCO25
Great to meet up with Sheffield colleagues, Sophie Trotter and Syed Hussain at #ASCO25
Sophie Trotter at #ASCO25 presenting frailty measures from the STAR renal cell cancer trial @fohsheffield.bsky.social @sheffieldteachinghospitals @universityofleeds.bsky.social
Data from randomized Ph 3 trial that studied time of day of immunotherapy infusion said that infusion before 3:00 PM is far superior to > 3:00 PM. Study by Yongchang Zhang & team. Circadian rhythms with potential major impact on T cell circulation & exhaustion. h/t @stephenvliu.bsky.social #ASCO25
Phase II ipi nivo rela with IL6 inhibitor sarilumab with ORR 68% - highest reported with IO - and grade 3/4 irAEs 12% - lowest reported with combination IO
Jan Mehnert @nyulangone.bsky.social
#ASCO25 @ascocancer.bsky.social @aspire-cop.bsky.social
Melanoma rapid #3 β‘οΈ High fiber diet of 30-50g daily is tolerable, pCR 57% in neoadj group, grade 3+ irAE 28.8%
Took 400 patients screened to enroll 45 π€
Yiufan Qiu @mdanderson.bsky.social
#ASCO25 @ascocancer.bsky.social
@aspire-cop.bsky.social
Metastatic mucosal melanoma today:
-combination immunotherapy shows lackluster efficacy
-MEKi with 25% ORR
-KIT + anti PD1 with 54.8% ORR
-triplet ICI with 33% ORR
-lenv pembro with 50% ORR
-TIL with 50% ORR
Jun Guo
#ASCO25 #raremelanoma #rarecancers @ascocancer.bsky.social
This is fascinating. When paired with the Manchester abstract @beckilee.bsky.social and colleagues presented, do we need to change practice now?
Also please contact ctrad@macmillan.org for a sign up form so you can be kept up to date with CT RAD activities, meetings and opportunities @ctrad.bsky.social @icr.ac.uk @profemmahall.bsky.social @montefiored.bsky.social
News for UK radiotherapy community.
Pleased to say that thanks to @macmillancancer we have been able to establish #ctrad.
We plan a proposals guidance meeting on 8.7.25
If you have a new trial idea and wish to attend please contact ctrad@macmillan.org to register
Well done @catrionamayland.bsky.social on this important work. Go Sheffield researchers @sheffielduni.bsky.social!